Milos Miljkovic MD

Hematologic Oncology

Chief Medical Officer, Cartesian Therapeutics

10 Center DrBG 10 RM 4N115Bethesda, MD 20814
Phone+1 301-250-5216

Dr. Miljkovic is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Miljkovic's full profile Already have an account?

Summary

Dr. Miloš Miljković is a hematologist/oncologist based in Brighton, CO. He completed his medical education at the University of Belgrade Faculty of Medicine in 2008 and pursued residency and fellowship training at Sinai Hospital of Baltimore and the National Cancer Institute, respectively. His experience encompasses hematology, oncology, lymphoma and myeloma. He has conducted research on IL-15 for treatment of various malignancies, and on cell therapies for treatment of autoimmune disease. Dr. Miljković also works as an Instructor at University of Maryland Baltimore County, where he co-leads an introductory course on clinical trials.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2017
Sinai Hospital of BaltimoreChief Residency, Internal Medicine, 2013 - 2014
Sinai Hospital of BaltimoreResidency, Internal Medicine, 2010 - 2013
University of Belgrade Faculty of MedicineClass of 2008

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CO State Medical License 2025 - 2027
DC State Medical License 2024 - 2027
MD State Medical License 2016 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Start of enrollment: 2017 Jan 19
COMPLETED
PHASE1
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Start of enrollment: 2019 Jul 11
TERMINATED
PHASE1
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Start of enrollment: 2019 Jun 07
COMPLETED
PHASE1

Publications & Presentations

PubMed

1 citations
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
Max J Gordon, Milos D Miljkovic, Paige Milhon, Rahul Lakhotia, Christopher Melani
Blood Advances. 2026-05-26
1 citations
PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance.
Marc Sorigue, Milos Miljkovic, Pablo Mozas
Blood Reviews. 2025-05-01
3 citations
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.
Max J Gordon, Sigrid Dubois, Milos D Miljkovic, Samuel Ng, Bonita Bryant
Blood Neoplasia. 2025-02-01

Abstracts/Posters

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
Milos D. Miljkovic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019